35 completed, 7 terminated, 5 withdrawn, 3 recruiting. 54 Phase 1, 21 Phase 2.
Follow Carmustine: new trials by email Literature Review of Carmustine trials Research Report on Carmustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tebentafusp-tebn With LDT in Metastatic UM Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU - Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | Thomas Jefferson University | 109 | 2025-10-15 | 2026-07-21 |
| Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Dapagliflozin, Carmustine, Topotecan - Pediatric Brain Tumor, Pediatric Solid Tumor | Phase 1 | Recruiting | Washington University School of Medicine | 20 | 2023-04-03 | 2026-06-10 |
| Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2023-04-01 | 2023-01-13 | |
| SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells Melphalan, BCNU, Vitamin B12B - Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation | Phase 1 | Recruiting | General Oncology, Inc. | 24 | 2021-01-13 | 2026-01-29 |
| Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma Yttrium Y 90 Basiliximab, Carmustine, Etoposide - Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | City of Hope Medical Center | 20 | 2020-06-08 | 2025-03-20 |
| A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma Selinexor, Temozolomide (TMZ), Lomustine (CCNU) - Glioblastoma Multiforme | Phase 1 / Phase 2 | Terminated | Karyopharm Therapeutics Inc | 74 | 2020-06-08 | 2024-12-16 |
| CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - CD19 Positive, Mantle Cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-10-03 | 2020-01-29 | |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
| Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects VBI-1901, Carmustine, Lomustine - Glioblastoma Multiforme | Phase 1 / Phase 2 | Terminated | VBI Vaccines Inc. | 70 | 2017-12-06 | 2026-05-08 |
| Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Blinatumomab, Autologous stem cell transplant, Carmustine - Diffuse Large B Cell Lymphoma | Phase 1 | Completed | Washington University School of Medicine | 14 | 2017-08-01 | 2023-11-28 |
| Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein, Autologous Hematopoietic Stem Cell Transplantation, Carmustine - Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 3 | 2017-02-01 | 2020-11-23 |
| HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs, Carmustine, Filgrastim - Human Immunodeficiency Virus 1 Positive, Stage I Adult Hodgkin Lymphoma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2016-08-15 | 2018-11-20 | |
| Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | AIDS Malignancy Consortium | 11 | 2016-06-23 | 2026-05-18 |
| Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma | Phase 1 | Completed | OHSU Knight Cancer Institute | 11 | 2015-07-20 | 2020-11-23 |
| Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis Autologous Hematopoietic Stem Cell, BEAM Regimen - Multiple Sclerosis | Phase 1 | Unknown | Makati Medical Center | 15 | 2015-05-29 | 2017-05-05 |
| Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma Bendamustine, Carmustine, Etoposide - Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Completed | Weill Medical College of Cornell University | 34 | 2014-06-04 | 2021-02-21 |
| Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 20 | 2013-10-09 | 2020-08-04 |
| High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma Carmustine, Etoposide, Cytarabine - Non-Hodgkin's Lymphoma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 17 | 2013-04-01 | 2026-05-28 |
| Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma basiliximab, carmustine, etoposide - Recurrent Adult Hodgkin Lymphoma | Phase 1 | Completed | City of Hope Medical Center | 25 | 2013-02-13 | 2026-10-15 |
| CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies Leukapheresis, Stem Cell Transplant, CD19-specific T Cell Infusion - Lymphoma, B-cell Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 34 | 2011-06-20 | 2023-12-19 |
Showing 20 of 54. Sign in to see all of them.
Central Nervous System Neoplasms (16) · Glioblastoma (16) · Lymphoma, Non-Hodgkin (14) · Gliosarcoma (13) · Astrocytoma (12) · Brain Neoplasms (11) · Lymphoma, Mantle-Cell (11) · Lymphoma (9) · Lymphoma, Large B-Cell, Diffuse (9) · Oligodendroglioma (9) · Lymphoma, Follicular (8) · Glioma (7) · Hodgkin Disease (7) · Burkitt Lymphoma (6) · Ependymoma (5)
Fred Hutchinson Cancer Center (6) · National Cancer Institute (NCI) (5) · City of Hope Medical Center (4) · Duke University (4) · M.D. Anderson Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · University of Nebraska (3) · Case Comprehensive Cancer Center (2) · Washington University School of Medicine (2) · AIDS Malignancy Consortium (1) · Alliance for Clinical Trials in Oncology (1) · Barbara Ann Karmanos Cancer Institute (1) · Barrett Cancer Center (1) · Beth Israel Deaconess Medical Center (1) · Darell D. Bigner, MD, PhD (1)
United States (52) · Canada (3) · Australia (1) · Germany (1) · Philippines (1)
Henry S. Friedman, MD (4) · Ajay Gopal (2) · Amrita Y. Krishnan, MD (2) · Julie M Vose, MD (2) · Kevin Cooper (2) · Aaron P. Rapoport, MD (1) · Alessandro Olivi, MD (1) · Andrew B Lassman, MD (1) · Andrew Cluster, M.D. (1) · Armin Ghobadi, M.D. (1) · Arnold Glazier, M.D. (1) · Craig Sauter, MD (1) · Darell D. Bigner, MD, PhD (1) · Darwin Albert A Dasig, MD (1) · David Avigan, MD (1)
PMID 34515338, PMID 12721262, PMID 17264335, PMID 17941066, PMID 18723297, PMID 19533025, PMID 20063115, PMID 22250189, PMID 23834234, PMID 25105369, PMID 27482888, PMID 28199478, PMID 29476021, PMID 30826465, PMID 31262783, PMID 32499241, PMID 33586581, PMID 34638132, PMID 37871306, PMID 38838232, PMID 41429239
P30CA015704 (4), U01CA062502 (3), P01CA044991 (2), P30CA043703 (2), P01CA030206 (1), P30CA016672 (1), P30CA022453 (1), P30CA033572 (1), P30CA036727 (1), R01CA141303 (1), R01HL116217 (1), R21CA076192 (1), R21CA115057 (1), R21CA185875 (1), U01CA121947 (1)